Dry powder inhaler products have played an important role in the treatment and prevention of asthma and more recently chronic obstructive pulmonary disease. The considerations that go into formulation development to support these products cover a unique range of disciplines including analytical and physical chemistry, aerosol physics, device technology, process engineering and industrial design. An enormous research effort has been expended in the last half century to provide understanding of this complex dosage form. The guiding principles in considering the development of dry powder inhaler products encompass requirements for disease therapy, advantages and limitations of adopting certain technological approaches, and desirable features to facilitate patient use, which are all embodied in the target product profile.
Get full access to this article
View all access options for this article.
References
1.
SandersM: Pulmonary drug delivery: An historical overview. In: Controlled Pulmonary Drug Delivery. (Smyth HDC, Hickey AJ. eds.) Springer: New York, NY, USA; 2011; pp. 51–73.
HickeyAJ.Pulmonary drug delivery—Pharmaceutical chemistry and aerosol technology. In: Drug Delivery Principles and Applications. (Wang B, Siahaan T, Soltero R. eds.) Wiley: New York, NY, USA; 2004.
5.
FarrSJ, TaylorG.Insulin inhalation: Its potential as a nonparenteral method of administration. In: Inhalation Delivery of Therapeutic Peptides and Proteins. (Adjei AL and Gupta PK. eds.) Marcel Dekker: New York, NY, USA; 1997; pp. 371–387.
6.
Apiou-SbirleaG, NewmanS, FlemingJ, et al.Bioequivalence of inhaled drugs: Fundamentals, challenges and perspectives. Ther Deliv, 2013; 4(3):343–367; doi: 10.4155/tde.12.161
7.
ShurJ, KubavatHA, RuecroftG, et al.Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations. J Pharm Pharmacol, 2012; 64(9):1326–1336; doi: 10.1111/j.2042-7158.2012.01522.x
8.
HickeyAJ.Lung deposition and clearance of pharmaceutical aerosols: What can be learned from inhalation toxicology and industrial hygiene?. Aerosol Sci Technol, 1993; 18(3):290–304; doi: 10.1080/02786829308959606
9.
SteckelH, BolzenN. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm, 2004; 270(1–2):297–306; doi: 10.1016/j.ijpharm.2003.10.039
10.
van OortMM, SacchettiM.Spray drying and supercritical fluid particle generation techniques. In: Inhalation Aerosols, Physical and Biological Basis for Therapy. (Hickey AJ, ed.) Informa Healthcare: New York, NY, USA; 2007; pp. 307–346.
CrowderTM, RosatiJA, SchroeterJD, et al.Fundamental effects of particle morphology on lung delivery: Predictions of stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res, 2022; 19(3):239–245; doi: 10.1023/A:1014426530935
13.
HickeyA.Summary of common approaches to pharmaceutical aerosol administration. In: Pharmaceutical Inhalation Aerosol Technology. (Hickey AJ, ed.) Marcel Dekker: New York, NY, USA; 2004; pp. 385–421.
14.
DunberCA, HickeyAJ, HolznerP. Dispersion and characterization of pharmaceutical dry powder aerosols. KONA Powder Part J, 1998; 16:7–45; doi: 10.14356/kona.1998007
15.
TelkoMJ, HickeyAJ. Dry powder inhaler formulation. Respir Care, 2005; 50(9):1209–1227.
16.
XuZ, MansourHM, HickeyAJ. Particle interactions in dry powder inhaler unit processes: A review. J Adhes Sci Technol, 2011; 25(4/5):451–482; doi: 10.1163/016942410X525669
17.
XuZ, HickeyAJ. A comparison of aerosol performance using standardized entrainment tubes vs. dry powder inhaler devices. KONA Powder Part J, 2013; 30:201–210; doi: 10.14356/kona.2013019
18.
JonesMD, PriceR. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res, 2006; 23(8):1665–1674; doi: 10.1007/s11095-006-9012-7
19.
BegatP, MortonDAV, StaniforthJN, et al.The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res, 2004; 21(9):1591–1597.
20.
LoueyMD, OortVM, HickeyAJ. RTI International—Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion. J Aerosol Sci, 2006; 37(11):1520–1531.
21.
XuZ, MansourHM, MulderT, et al.Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. J Pharm Sci, 2010; 99(8):3442–3461; doi: 10.1002/jps.22057
22.
GrasmeijerF, HagedoornP, FrijlinkHW, et al.Drug content effects on the dispersion performance of adhesive mixtures for inhalation. PLoS One, 2013; 8(8):e71339; doi: 10.1371/journal.pone.0071339
23.
YoungPM, CocconiD, ColomboP, et al.Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing.”. J Pharm Pharmacol, 2002; 54(10):1339–1344; doi: 10.1211/002235702760345400
24.
YoungPM, ChanH-K, ChiouH, et al.The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. J Pharm Sci, 2007; 96(5):1331–1341; doi: 10.1002/jps.20933
25.
ZhouQT, QuL, GengenbachT, et al.Effect of surface coating with magnesium stearate via mechanical dry powder coating approach on the aerosol performance of micronized drug powders from dry powder inhalers. AAPS PharmSciTech, 2013; 14(1):38–44; doi: 10.1208/s12249-012-9895-z
CrowderTM, LoueyMD, SethuramanVV, et al.RTI International—2001: An odyssey in inhaler formulation and design. Pharm Technol, 2001; 25(7):99–113.
28.
US Food and Drug Adminstration, Draft Guidance for the Industry, Metered Dose inhaler (MDI and Dry Powder Inhaler (DPI) Chemistry, Manufacturing and Controls Documentation. Available from: www.fda.gov/downloads/Drugs/Guidances/ucm070573.pdf
HickeyA.Lung deposition and clearance: What can be learned from inhalation toxicology and industrial hygiene?. Aerosol Sci Tech, 1993; 18:290–304; doi: 10.1080/02786829308959606
31.
XuJ, WongDHC, ByrneJD, et al.Future of the particle replication in nonwetting templates (PRINT) technology. Angew Chem Int Ed Engl, 2013; 52(26):6580–6589; doi: 10.1002/anie.201209145
